MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $23.08 Average Target Price from Analysts

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been given an average recommendation of “Hold” by the sixteen ratings firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.0769.

MLTX has been the subject of several analyst reports. Needham & Company LLC upped their price target on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Zacks Research upgraded MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Oppenheimer increased their price objective on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a research report on Friday, January 9th. Finally, Royal Bank Of Canada increased their price objective on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock opened at $18.43 on Tuesday. MoonLake Immunotherapeutics has a 12 month low of $5.95 and a 12 month high of $62.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 9.27 and a quick ratio of 9.27. The business has a 50 day simple moving average of $17.22 and a 200-day simple moving average of $14.61. The stock has a market capitalization of $1.32 billion, a PE ratio of -5.24 and a beta of 1.19.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting the consensus estimate of ($0.92). During the same period in the previous year, the firm posted ($0.72) EPS. Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $16.79, for a total value of $62,962,500.00. Following the completion of the transaction, the director owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 12.05% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new position in MoonLake Immunotherapeutics in the fourth quarter worth $26,000. Russell Investments Group Ltd. raised its position in MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after acquiring an additional 1,069 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics in the fourth quarter worth $47,000. FNY Investment Advisers LLC acquired a new stake in MoonLake Immunotherapeutics in the third quarter valued at $28,000. Finally, Bank of America Corp DE grew its holdings in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after purchasing an additional 1,781 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.